The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00001373
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : June 7, 2024
Sponsor:
Collaborators:
University of Massachusetts, Worcester
Duke University
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )

Brief Summary:

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.

The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

Patients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following:

  1. X-rays
  2. Consultations with specialists
  3. DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome.
  4. Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness)
  5. Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm.

Patients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options.

Participating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness).

Relatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above.

Normal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future.


Condition or disease
Familial Mediterranean Fever (FMF) Autoinflammation Periodic Fever Fever Genetic Diseases ROSAH ALPK1

Detailed Description:
This is an exploratory natural history protocol that enrolls patients with known or as yet undiagnosed disorders of inflammation. Blood, saliva, or buccal samples will be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, a small number of subjects may undergo skin biopsy, leukapheresis, or bone marrow aspiration and biopsy, and some subjects will be provided standard medical care follow up, with retrospective analysis of the clinical data gathered during follow up. The primary objective is to discover the genetic basis of human disorders of inflammation. The secondary objective is to enumerate immunologic features and genotype-phenotype associations in specific autoinflammatory diseases. The tertiary objective is to describe the clinical features of poorly characterized or newly defined disorders of inflammation. This protocol provided clinical support for the identification of the gene mutated in familial Mediterranean fever (FMF), the discovery of the TNF receptor-associated periodic syndrome (TRAPS), the identification of NLRP3 mutations in the neonatal-onset multisystem inflammatory disease (NOMID), the discovery of the deficiency of the IL-1 receptor antagonist (DIRA), and the proposal of the now widely accepted concept of autoinflammatory disease. During the last decade the protocol has provided the clinical foundation for the discovery of ten more monogenic autoinflammatory diseases, seven of which were previously unrecognized as distinct diseases. The protocol has also permitted numerous studies delineating the mechanisms of autoinflammation and its connections with the human innate immune system. The work catalyzed by this protocol has provided the conceptual basis for a number of targeted therapies. During the next decade the objective will be to utilize cutting edge genomic technologies to further advance discovery.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 5000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases
Actual Study Start Date : March 10, 1994


Group/Cohort
Affected
Patients with auto-inflammatory disorders
Family Members
Family members of patients
Healthy Volunteers
Healthy Volunteers



Primary Outcome Measures :
  1. Genetic linkage in autoinflammatory dise [ Time Frame: annually ]
    discovery of genetic associations to autoinflammatory disorders



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 115 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with autoinflammatory disorders and unaffected family members, and healthy volunteers.
Criteria
  • INCLUSION CRITERIA:

There are three populations that will be included in this study: subjects with known or suspected autoinflammatory diseases, family members of subjects with known or suspected autoinflammatory diseases, and healthy controls. In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:

  1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
  2. Regardless of gender, at least one month of age;
  3. A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and
  4. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.

In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:

  1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
  2. Regardless of gender, at least one month of age;
  3. Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;
  4. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possible autoinflammatory condition; and
  5. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.

In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:

  1. Stated willingness to participate in study procedures for healthy volunteers;
  2. Regardless of gender, at least one year old, and not pregnant (by history of a missed menstrual period);
  3. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and
  4. Ability of the subject or parents (in the case of children) to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

For any of the three categories of subjects, an individual will be excluded from participation in this study if he or she has a medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001373


Contacts
Layout table for location contacts
Contact: Amanda K Ombrello, M.D. (301) 827-4258 ombrelloak@mail.nih.gov
Contact: Daniel L Kastner, M.D. (301) 496-8364 kastnerd@mail.nih.gov

Locations
Layout table for location information
United States, District of Columbia
Childrens National Medical Center Completed
Washington, District of Columbia, United States, 20010
United States, Maryland
Johns Hopkins University Completed
Baltimore, Maryland, United States, 21205
Walter Reed National Medical Center Completed
Bethesda, Maryland, United States, 20301
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: NIH Clinical Center Office of Patient Recruitment (OPR)    800-411-1222 ext TTY dial 711    ccopr@nih.gov   
United States, Pennsylvania
University of Pittsburgh Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15261
Contact: Daniella Schwartz    412-648-1587    Daniella.Schwartz@pitt.edu   
Sponsors and Collaborators
National Human Genome Research Institute (NHGRI)
University of Massachusetts, Worcester
Duke University
Merck Sharp & Dohme LLC
Investigators
Layout table for investigator information
Principal Investigator: Daniel L Kastner, M.D. National Human Genome Research Institute (NHGRI)
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: National Human Genome Research Institute (NHGRI)
ClinicalTrials.gov Identifier: NCT00001373    
Other Study ID Numbers: 940105
94-HG-0105
First Posted: November 4, 1999    Key Record Dates
Last Update Posted: June 7, 2024
Last Verified: June 5, 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: .Individual genomic sequencing data and corresponding phenotype data will be deposited in dbGaP as part of the study's Genomic Data Sharing Plan. Non-genomic and/or phenotypic individual data will not be deposited in shared databases for broad research use.
Supporting Materials: Study Protocol
Analytic Code
Time Frame: Genomic Sharing Plan in effect since 2018 with genomic data deposited to dbGaP for broad availability within six months of final data analysis of each genomic sequence. No end date of data availability through dbGaP.
Access Criteria: Genomic sequences will be deposited to dbGaP following final sequence analysis and available for broad use, as determined by dbGaP usage committee.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):
Splenomegaly
Retinal Dystrophy
Periodic Fever
Optic Nerve Edema
HEADACHE
Genetics
Familial Mediterranean
Autoinflammation
Anhidrosis
Alpha-Kinase 1
Additional relevant MeSH terms:
Layout table for MeSH terms
Hereditary Autoinflammatory Diseases
Brucellosis
Genetic Diseases, Inborn
Familial Mediterranean Fever
Fever
Hyperthermia
Body Temperature Changes
Heat Stress Disorders
Wounds and Injuries
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections
Skin Diseases, Genetic
Skin Diseases